TMCnet News
UroGen Pharma Announces Proposed Public Offering of Ordinary SharesRA’ANANA, Israel and NEW YORK, Jan. 16, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) in connection with a public offering of 1,135,847 ordinary shares. The company intends to grant the underwriters a 30-day option to purchase 170,377 additional ordinary shares at the public offering price, less the underwriting discounts and commissions. All ordinary shares to be sold in the offering will be offered by the company. Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Oppenheimer & Co. Inc. and National Securities Corporation are acting as co-managers for the offering. A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained rom Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: [email protected], or from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140. About UroGen Pharma Ltd. Forward Looking Statements UROGEN CONTACTS: Christine Cassiano Kate Bechtold |